UBS Group reports 5.46% stake in Amicus Therapeutics

Amicus Therapeutics reports that UBS Group and its subsidiaries beneficially own 17,141,817 shares of Common Stock, representing 5.46% of the class.

Rhea-AI Filing Summary

Amicus Therapeutics reports that UBS Group and its subsidiaries beneficially own 17,141,817 shares of Common Stock, representing 5.46% of the class. The filing states UBS Group AG filed on behalf of UBS Financial Services Inc., UBS Securities LLC, UBS AG London Branch and UBS Switzerland AG. The filer reports shared voting power of 17,071,007 shares and shared dispositive power of 14,222,423.

Insights

Institutional Ownership Analyst

UBS Group reports a passive 5.46% stake in Amicus held across multiple subsidiaries.

UBS Group AG filed a Schedule 13G disclosing beneficial ownership of 17,141,817 shares of Common Stock, representing 5.46% of the class. The filing attributes shared voting power of 17,071,007 and shared dispositive power of 14,222,423 to the reporting group and names four subsidiaries in the exhibit.

The filing style and the 13G form suggest an investment reported as passive under Section 13(g). Subsequent filings or amendments would be required if ownership or intentions change.

Key Figures

Beneficial ownership: 17,141,817 shares Percent of class: 5.46% Shared voting power: 17,071,007 shares +2 more

5 metrics

Beneficial ownership 17,141,817 shares Amount beneficially owned reported on Schedule 13G

Percent of class 5.46% Percent of class reported in Item 4(a)/(b)

Shared voting power 17,071,007 shares Number of shares with shared power to vote (Item 4(c)(ii))

Shared dispositive power 14,222,423 shares Number of shares with shared power to dispose (Item 4(c)(iv))

Filing form Schedule 13G Form type filed for beneficial ownership disclosure

Key Terms

Schedule 13G, Beneficially owned, Shared dispositive power, Shared voting power

4 terms

Schedule 13G regulatory

"Item 1. Name of issuer: AMICUS THERAPEUTICS, INC."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficially owned financial

"Item 4. Amount beneficially owned: 17,141,817"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Shared dispositive power financial

"Shared power to dispose or to direct the disposition of: 14,222,423"

Shared voting power financial

"Shared power to vote or to direct the vote: 17,071,007"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does UBS Group report in Amicus Therapeutics (FOLD)?

UBS Group reports beneficial ownership of 17,141,817 shares, equal to 5.46% of the class. The Schedule 13G shows shared voting power of 17,071,007 and shared dispositive power of 14,222,423 across named subsidiaries.

Who filed the Schedule 13G for Amicus Therapeutics (FOLD)?

The Schedule 13G was filed by UBS Group AG on behalf of itself and subsidiaries. The exhibit lists UBS Financial Services Inc., UBS Securities LLC, UBS AG London Branch, and UBS Switzerland AG as relevant subsidiaries.

Does the filing indicate UBS plans to control Amicus Therapeutics?

No control intent is stated; the filing reports shared voting and dispositive power totals but does not assert control. The Schedule 13G format typically reflects a passive investment reported under Section 13(g).

What powers does UBS report over the shares of Amicus Therapeutics?

UBS reports 0 sole voting and dispositive power, 17,071,007 shared voting power, and 14,222,423 shared dispositive power. These figures are disclosed in Item 4 of the Schedule 13G.

Does the Schedule 13G list the filing date and signature?

The filing shows an action date 03/31/2026 and is signed by Andrew Johnson as Director on 05/07/2026. The statement identifies UBS Group AG as the filer representing multiple subsidiaries.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 11:28 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

AMICUS THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

03152W109

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 03152W109

1

Names of Reporting Persons

UBS Group AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 17,071,007.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 14,222,423.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

17,141,817.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

BK

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AMICUS THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 47 HULFISH STREET, PRINCETON, NEW JERSEY, 08542
Item 2.
(a)	Name of person filing: UBS Group AG
(b)	Address or principal business office or, if none, residence: Bahnhofstrasse 45 PO Box CH-8021, Zurich, Switzerland
(c)	Citizenship: Switzerland
(d)	Title of class of securities: Common Stock, par value $0.01 per share
(e)	CUSIP Number(s): 03152W109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 17,141,817
(b)	Percent of class: 5.46 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 17,071,007
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 14,222,423
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement on Schedule 13G is being filed by UBS Group AG on behalf of itself and its wholly owned subsidiaries UBS Financial Services Inc.,UBS Securities LLC,UBS AG London Branch and UBS Switzerland AG.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

UBS Group AG

Signature:	Andrew Johnson
Name/Title:	Director
Date:	05/07/2026